About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Metformin , dose 2

Company: Chipscreen Biosciences, Ltd.
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 24, 2026

Trial details

Completed NCT NCT00382096

Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 1179 participants Est. completion 2008-06-03 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT07519265

Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets

Not yet reported Chipscreen Biosciences, Ltd. 64 participants Est. completion 2026-08-03 1 site Stand-alone

Type 2 diabetes
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07519265

Also known as: Metformin , dose 2, Metformin extended-release tablet, dose 2

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.